151 related articles for article (PubMed ID: 25854294)
1. Burden of stroke in Italy: an economic model highlights savings arising from reduced disability following thrombolysis.
Chiumente M; Gianino MM; Minniti D; Mattei TJ; Spass B; Kamal KM; Zimmerman DE; Muca A; Luda E
Int J Stroke; 2015 Aug; 10(6):849-55. PubMed ID: 25854294
[TBL] [Abstract][Full Text] [Related]
2. Acute Ischemic Stroke (AIS) patient management in French stroke units and impact estimation of thrombolysis on care pathways and associated costs.
Schmidt A; Heroum C; Caumette D; Le Lay K; Bénard S
Cerebrovasc Dis; 2015; 39(2):94-101. PubMed ID: 25660476
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
[TBL] [Abstract][Full Text] [Related]
4. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
Lorenzano S; Toni D;
Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
[TBL] [Abstract][Full Text] [Related]
5. Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
Quinn TJ; Dawson J
Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):513-22. PubMed ID: 19941428
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
Ehlers L; Andersen G; Clausen LB; Bech M; Kjølby M
Stroke; 2007 Jan; 38(1):85-9. PubMed ID: 17122430
[TBL] [Abstract][Full Text] [Related]
7. Potential gains and costs from increasing access to thrombolysis for acute ischemic stroke patients in New Zealand hospitals.
Te Ao B; Brown P; Fink J; Vivian M; Feigin V
Int J Stroke; 2015 Aug; 10(6):903-10. PubMed ID: 24206567
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom.
Earnshaw SR; McDade C; Chapman AM; Jackson D; Schwamm L
Clin Ther; 2012 Jul; 34(7):1544-58. PubMed ID: 22695225
[TBL] [Abstract][Full Text] [Related]
9. [Economic evaluation of the stroke units in Campania].
Scaletti A; Lauro E; Belfiore P; Zamparelli B; Liguori G;
Ig Sanita Pubbl; 2014; 70(1):57-79. PubMed ID: 25006858
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation.
Gerzeli S; Tarricone R; Zolo P; Colangelo I; Busca MR; Gandolfo C
Neurol Sci; 2005 Jun; 26(2):72-80. PubMed ID: 15995823
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of thrombolytic treatment for stroke.
Mar J; Begiristain JM; Arrazola A
Cerebrovasc Dis; 2005; 20(3):193-200. PubMed ID: 16088115
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China.
Pan Y; Chen Q; Zhao X; Liao X; Wang C; Du W; Liu G; Liu L; Wang C; Wang Y; Wang Y;
PLoS One; 2014; 9(10):e110525. PubMed ID: 25329637
[TBL] [Abstract][Full Text] [Related]
13. Budget impact analysis of thrombolysis for stroke in Spain: a discrete event simulation model.
Mar J; Arrospide A; Comas M
Value Health; 2010; 13(1):69-76. PubMed ID: 19818059
[TBL] [Abstract][Full Text] [Related]
14. Hospitalization costs for acute ischemic stroke patients treated with intravenous thrombolysis in the United States are substantially higher than medicare payments.
Brinjikji W; Rabinstein AA; Cloft HJ
Stroke; 2012 Apr; 43(4):1131-3. PubMed ID: 22198978
[TBL] [Abstract][Full Text] [Related]
15. A simple risk index and thrombolytic treatment response in acute ischemic stroke.
Ovbiagele B; Reeves MJ; Nasiri M; Johnston SC; Bath PM; Saposnik G;
JAMA Neurol; 2014 Jul; 71(7):848-54. PubMed ID: 24798141
[TBL] [Abstract][Full Text] [Related]
16. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment.
Nesi M; Lucente G; Nencini P; Fancellu L; Inzitari D
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):204-8. PubMed ID: 23352114
[TBL] [Abstract][Full Text] [Related]
17. Real-life costs and effects of an implementation program to increase thrombolysis in stroke.
Dirks M; Baeten SA; Dippel DW; van Exel NJ; van Wijngaarden JD; Huijsman R; Koudstaal PJ; Niessen LW;
Neurology; 2012 Aug; 79(6):508-14. PubMed ID: 22786601
[TBL] [Abstract][Full Text] [Related]
18. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
[TBL] [Abstract][Full Text] [Related]
19. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study.
García-Bermejo P; Calleja AI; Pérez-Fernández S; Cortijo E; del Monte JM; García-Porrero M; Fe Muñoz M; Fernández-Herranz R; Arenillas JF
Cerebrovasc Dis; 2012; 34(1):31-7. PubMed ID: 22759450
[TBL] [Abstract][Full Text] [Related]
20. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an observational study.
Ahmed N; Kellert L; Lees KR; Mikulik R; Tatlisumak T; Toni D;
JAMA Neurol; 2013 Jul; 70(7):837-44. PubMed ID: 23689267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
